FAQ: Sapu Nano's Sapu003 Clinical Trial Approval for Breast Cancer Treatment

What is the main announcement in this content?

Sapu Nano has received approval from Australia’s Human Research Ethics Committee to begin enrolling patients in clinical trials for Sapu003, an injectable form of Everolimus for breast cancer treatment.

What is Sapu003 and how does it work?

Sapu003 is an injectable form of Afinitor (Everolimus) that uses Sapu Nano’s Deciparticle technology to deliver more of the Everolimus drug into the bloodstream, potentially making it more effective than taking the drug in pill form.

Who is involved in this development?

Sapu Nano is part of a family of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited.

Where are the clinical trials taking place?

The clinical trials are being conducted in Australia, as approval was granted by Australia’s Human Research Ethics Committee.

Why is this development significant for breast cancer treatment?

This is significant because Sapu003’s injectable formulation using Deciparticle technology could deliver more Everolimus into the bloodstream, potentially providing more effective treatment compared to traditional pill forms of the drug.

What is Everolimus and what is it currently used for?

Everolimus (marketed as Afinitor) is an FDA-approved drug for treating different types of advanced cancer including breast cancer, kidney cancer, and other affiliated conditions.

What stage of development is Sapu003 currently in?

Sapu003 has received approval to begin human clinical trials and is now starting patient enrollment, indicating it’s moving into the clinical testing phase.

How can I get more information about Oncotelic Therapeutics?

For more information about Oncotelic Therapeutics, visit their website at www.oncotelic.com or access their newsroom at ibn.fm/OTLC.

What makes Sapu003 different from existing Everolimus treatments?

Sapu003 differs from existing treatments by being an injectable formulation that uses Deciparticle technology, which is designed to deliver more of the drug into the bloodstream compared to the traditional pill form of Everolimus.